Limits...
Cytokeratin19-2g2, a novel fragment of cytokeratin19 in serum, indicating a more invasive behavior and worse prognosis in breast cancer patients.

Kong Y, Wang J, Liu W, Chen Q, Yang J, Wei W, Wu M, Yang L, Xie X, Lv N, Guo J, Li L, Gao J, Xie X, Dai S - PLoS ONE (2013)

Bottom Line: However, so far, few markers have been proved clinically useful except CA153.The sensitivities of CK19-2G2 for breast carcinoma are as high as CEA and CA153, and up to 71% in MBC patients.Serum CK19-2G2 levels (≥2 mU/mL) were associated with pathological stages, tumor size (≥2 cm), lymph node involvement, and HER2 status.

View Article: PubMed Central - PubMed

Affiliation: Department of Breast Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, PR China.

ABSTRACT

Background: Various studies have been searching for new tumor biomarkers for breast cancer for years. However, so far, few markers have been proved clinically useful except CA153. Based on knowledge that most adenocarcinomas including breast carcinoma expressed Cytokeratin19, the authors studied CK19-2G2,a novel fragment of cytokeratin19 shedding into serum in breast cancer patients.

Patients and methods: The serum samples of four hundred and seventeen patients including three hundred and three (fifty-four DCIS and two hundred and forty-nine stage I-III) PBC patients and one hundred and fourteen MBC patients, eighty-one healthy controls and twenty-one breast benign disease patients were provided for measurement of CK19-2G2, CEA and CA153.The correlation between clinicopathological characters, prognosis and CK19-2G2 levels was further studied.

Results: The serum CK19-2G2 levels in breast cancer patients were significantly higher than that in healthy and benign controls. For breast cancer patients, CK19-2G2 levels in MBC were significantly higher than that in PBC patients. The sensitivities of CK19-2G2 for breast carcinoma are as high as CEA and CA153, and up to 71% in MBC patients. Serum CK19-2G2 levels (≥2 mU/mL) were associated with pathological stages, tumor size (≥2 cm), lymph node involvement, and HER2 status. Multivariate analysis revealed that high serum CK19-2G2 level was an independent factor for relapse (P = 0.029) and death (P = 0.040) in breast cancer patients.

Conclusion: Serum CK19-2G2 may be an independent indicator for prognosis and a candidate marker for monitoring metastasis in breast cancer.

Show MeSH

Related in: MedlinePlus

Survival curves for DFS and OS in breast cancer patients according to serum CK19-2G2 levels.(A) Kaplan-Meier survival curve showed that patients with high serum CK19-2G2 levels (≥2 mU/mL) had a significantly shorter disease free survival(P = 0.029) than those with lower levels(<2 mU/mL). (B) Kaplan-Meier survival curve showed that patients with high serum CK19-2G2 levels (≥2 mU/mL) had a significantly shorter overall survival(P = 0.040) than those with lower levels(<2 mU/mL).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3585311&req=5

pone-0057092-g003: Survival curves for DFS and OS in breast cancer patients according to serum CK19-2G2 levels.(A) Kaplan-Meier survival curve showed that patients with high serum CK19-2G2 levels (≥2 mU/mL) had a significantly shorter disease free survival(P = 0.029) than those with lower levels(<2 mU/mL). (B) Kaplan-Meier survival curve showed that patients with high serum CK19-2G2 levels (≥2 mU/mL) had a significantly shorter overall survival(P = 0.040) than those with lower levels(<2 mU/mL).

Mentions: There were 10 (28.6%) events in 35 patients with high serum CK19-2G2 levels and 41 events (19.4%) in 211 patients with low serum CK19-2G2 levels. Breast cancer patients with high serum CK19-2G2 levels (≥2 mU/mL) had a significantly shorter disease free survival(P = 0.029) (Figure 3A) and overall survival (P = 0.040) than those with lower levels (Figure 3B). A univariate analysis of survival showed that patients with post-menopasal, larger size (≥2 cm), positive lymph nodes, negative ER status, positive HER2 status and high serum CK19-2G2 levels had significantly shorter survival. Age and PR status did not appear to have any impact on prognosis (Table 3). Furthermore, significant variables found in univariate analysis were reanalyzed by multivariate analysis on prognosis. Unlike the results from univariate analysis, only serum CK19-2G2 as well as lymph nodes was showed to be an independent prognostic indicator.


Cytokeratin19-2g2, a novel fragment of cytokeratin19 in serum, indicating a more invasive behavior and worse prognosis in breast cancer patients.

Kong Y, Wang J, Liu W, Chen Q, Yang J, Wei W, Wu M, Yang L, Xie X, Lv N, Guo J, Li L, Gao J, Xie X, Dai S - PLoS ONE (2013)

Survival curves for DFS and OS in breast cancer patients according to serum CK19-2G2 levels.(A) Kaplan-Meier survival curve showed that patients with high serum CK19-2G2 levels (≥2 mU/mL) had a significantly shorter disease free survival(P = 0.029) than those with lower levels(<2 mU/mL). (B) Kaplan-Meier survival curve showed that patients with high serum CK19-2G2 levels (≥2 mU/mL) had a significantly shorter overall survival(P = 0.040) than those with lower levels(<2 mU/mL).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3585311&req=5

pone-0057092-g003: Survival curves for DFS and OS in breast cancer patients according to serum CK19-2G2 levels.(A) Kaplan-Meier survival curve showed that patients with high serum CK19-2G2 levels (≥2 mU/mL) had a significantly shorter disease free survival(P = 0.029) than those with lower levels(<2 mU/mL). (B) Kaplan-Meier survival curve showed that patients with high serum CK19-2G2 levels (≥2 mU/mL) had a significantly shorter overall survival(P = 0.040) than those with lower levels(<2 mU/mL).
Mentions: There were 10 (28.6%) events in 35 patients with high serum CK19-2G2 levels and 41 events (19.4%) in 211 patients with low serum CK19-2G2 levels. Breast cancer patients with high serum CK19-2G2 levels (≥2 mU/mL) had a significantly shorter disease free survival(P = 0.029) (Figure 3A) and overall survival (P = 0.040) than those with lower levels (Figure 3B). A univariate analysis of survival showed that patients with post-menopasal, larger size (≥2 cm), positive lymph nodes, negative ER status, positive HER2 status and high serum CK19-2G2 levels had significantly shorter survival. Age and PR status did not appear to have any impact on prognosis (Table 3). Furthermore, significant variables found in univariate analysis were reanalyzed by multivariate analysis on prognosis. Unlike the results from univariate analysis, only serum CK19-2G2 as well as lymph nodes was showed to be an independent prognostic indicator.

Bottom Line: However, so far, few markers have been proved clinically useful except CA153.The sensitivities of CK19-2G2 for breast carcinoma are as high as CEA and CA153, and up to 71% in MBC patients.Serum CK19-2G2 levels (≥2 mU/mL) were associated with pathological stages, tumor size (≥2 cm), lymph node involvement, and HER2 status.

View Article: PubMed Central - PubMed

Affiliation: Department of Breast Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, PR China.

ABSTRACT

Background: Various studies have been searching for new tumor biomarkers for breast cancer for years. However, so far, few markers have been proved clinically useful except CA153. Based on knowledge that most adenocarcinomas including breast carcinoma expressed Cytokeratin19, the authors studied CK19-2G2,a novel fragment of cytokeratin19 shedding into serum in breast cancer patients.

Patients and methods: The serum samples of four hundred and seventeen patients including three hundred and three (fifty-four DCIS and two hundred and forty-nine stage I-III) PBC patients and one hundred and fourteen MBC patients, eighty-one healthy controls and twenty-one breast benign disease patients were provided for measurement of CK19-2G2, CEA and CA153.The correlation between clinicopathological characters, prognosis and CK19-2G2 levels was further studied.

Results: The serum CK19-2G2 levels in breast cancer patients were significantly higher than that in healthy and benign controls. For breast cancer patients, CK19-2G2 levels in MBC were significantly higher than that in PBC patients. The sensitivities of CK19-2G2 for breast carcinoma are as high as CEA and CA153, and up to 71% in MBC patients. Serum CK19-2G2 levels (≥2 mU/mL) were associated with pathological stages, tumor size (≥2 cm), lymph node involvement, and HER2 status. Multivariate analysis revealed that high serum CK19-2G2 level was an independent factor for relapse (P = 0.029) and death (P = 0.040) in breast cancer patients.

Conclusion: Serum CK19-2G2 may be an independent indicator for prognosis and a candidate marker for monitoring metastasis in breast cancer.

Show MeSH
Related in: MedlinePlus